Compare TG Therapeutics Inc (TGTX) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B). The key difference: TG Therapeutics Inc is far larger — about 2.1× Direxion Daily TSLA Bull 2X Shares's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| TGTX | TSLL | |
|---|---|---|
Market Cap | $8.16B | $3.97B |
Volume | 1,735,121 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $59.06 | $23.03 |
52-Week Low | $26.94 | $6.74 |
Typical Hold Time | 16 Days | 15 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
TSLL, a leveraged ETF tracking Tesla, trades at $10.01, down 1.38% amid neutral technical signals. Moving averages suggest a bullish trend, but RSI indicates overbought conditions. The ETF lacks traditional financial ratios due to its structure, and recent news highlights its volatility tied to Tesla's Cybercab event.
Outlook hinges on Tesla's performance, offering amplified gains but high risk from daily rebalancing. Investors face significant volatility and potential decay, requiring careful risk management given the leveraged nature and dependence on Tesla's stock movements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
